Publications by authors named "R Sorouri"
The present study aims to provide an insight to the comprehensive efforts of Pasteur Institute of Iran (PII) regarding COVID-19 management, research, achievements, and vaccine production, though there are many challenges. The relevant literature review was investigated through national and international database and also reports from the related research departments. Six strategies were taken by PII to manage the pandemic of COVID-19.
View Article and Find Full Text PDFArticle Synopsis
- This study evaluated the effectiveness of the PastoCovac Plus vaccine as a booster compared to the original vaccines (ChAdOx1-S and BBIBP-CorV) in volunteers who had already received two doses of either.
- A total of 194 previously vaccinated participants were divided into groups to receive either the PastoCovac Plus or another dose of their initial vaccine, with serum samples collected before and four weeks after the booster to measure antibody levels.
- Results showed significant increases in anti-spike IgG levels for those receiving the PastoCovac Plus booster, with no notable differences in neutralizing antibody levels, indicating that both booster options are similarly effective.
Article Synopsis
- The COVID-19 pandemic's management included global vaccination, but concerns arose about antibody decline following various vaccines.
- A study investigated the effectiveness of the PastoCovac Plus protein subunit booster in healthcare workers who had been vaccinated with COVAXIN, highlighting the need for boosters at least three months after the second dose.
- The findings revealed significant increases in neutralizing and anti-Spike antibodies, but a notable percentage of participants remained seronegative for these antibodies, underscoring the importance of booster vaccinations to combat variants like Delta.
Early reports on coronavirus disease 2019 (COVID-19) vaccines presented the short-term adverse events (AEs). This follow-up study investigated a standard regimen based on protein subunit vaccines, PastoCovac and PastoCovac Plus, and the combinational vaccine regimens including AstraZeneca/PastoCovac Plus and Sinopharm/PastoCovac Plus. The participants were followed up to 6 months post the booster shot.
View Article and Find Full Text PDFThe optimal booster vaccine schedule against COVID-19 is still being explored. The present study aimed at assessment of the immunogenicity and antibody persistency of inactivated-virus based vaccine, BBIP-CorV and protein-subunit based vaccines, PastoCovac/Plus through heterologous and homologous prime-boost vaccination. Totally, 214 individuals who were previously primed with BBIBP-CorV vaccines were divided into three arms on their choice as heterologous regimens BBIBP-CorV/PastoCovac (n = 68), BBIBP-CorV/PastoCovac Plus (n = 72) and homologous BBIBP-CorV (n = 74).
View Article and Find Full Text PDF